AVAI (Avai Bio) Accounts Payable & Accrued Expense: $1.73 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVAI Avai Bio Inc AVAI
22 GF Score
Price $0.12
! 3 Warning Signs
View Full Analysis

What is Avai Bio Accounts Payable & Accrued Expense?

Avai Bio AVAI 22 Accounts Payable & Accrued Expense is $1.73 Mil as of Jun. 2026. GuruFocus rates AVAI with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Avai Bio's quarterly accounts payable & accrued expense increased from Dec. 2025 ($1.40 Mil) to Mar. 2026 ($1.59 Mil) and increased from Mar. 2026 ($1.59 Mil) to Jun. 2026 ($1.73 Mil).

Avai Bio's annual accounts payable & accrued expense declined from Mar. 2024 ($1.08 Mil) to Mar. 2025 ($0.89 Mil) but then increased from Mar. 2025 ($0.89 Mil) to Mar. 2026 ($1.59 Mil).

Avai Bio Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Avai Bio's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avai Bio Accounts Payable & Accrued Expense Chart

Avai Bio Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only 0.20 0.24 1.08 0.89 1.59

Avai Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.12 1.21 1.40 1.59 1.73
AVAI
22GF Score
Avai Bio Inc AVAI
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avai Bio Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of $1.73 Mil mean?
Avai Bio (AVAI) has a Accounts Payable & Accrued Expense of $1.73 Mil as of Jun. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Avai Bio and its competitors.
Is Avai Bio's Accounts Payable & Accrued Expense too high?
Avai Bio's current Accounts Payable & Accrued Expense is $1.73 Mil. Overall, Avai Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's Accounts Payable & Accrued Expense compare to IPM and CRMZ?
Avai Bio's Accounts Payable & Accrued Expense of $1.73 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Software company?
A good Accounts Payable & Accrued Expense depends on the Software industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Avai Bio and its competitors. Avai Bio's current Accounts Payable & Accrued Expense is $1.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current Accounts Payable & Accrued Expense of $1.73 Mil. The current Accounts Payable & Accrued Expense is $1.73 Mil. Avai Bio's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Avai Bio (AVAI), the current Accounts Payable & Accrued Expense is $1.73 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avai Bio Business Description

Address 5348 Vegas Drive, Las Vegas, NV, USA, 89108
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
22GF Score

Get the complete analysis for AVAI

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price